Synaffix inks $246m deal with ProfoundBioSynaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal more ➔
Panakès expands into biotech with €150m...Italian venture capital firm Panakès Partners, previously active in medtech, has closed the €150m purple fund with the goal to invest in underserved European Life Science companies. more ➔
BioNTech takes over cancer immunotherapy p...Mainz-based BioNTech is expanding its portfolio for cancer therapies with the neoantigen TCR Cell Therapy R&D pipeline and manufacturing site from Gilead Science subsidiary Kite Pharmaceuticals. more ➔
Nanosyrinx raises £6.2m to validate drug...Coventry-based NanoSyrinx plc has raised £6.2m in seed financing to develop a new cell engineering tool for novel targeted therapeutic modalities. more ➔
€26m financing for ISA PharmaceuticalsDutch immunotherapy company ISA Pharmaceuticals has closed a €26m funding round that will go towards advancing its therapy targeting HPV16-related cancers. more ➔
Unilever licences Arzeda Inc.s enzyme te...As part of its ‘Clean Future’ strategy, Unilever NV has licensed enzyme technology from Arzeda Inc. to help rid detergent production of fossil carbon. more ➔
Novo Nordisk invests in amyloidosis pipeli...Danish Novo Nordisk is moving out of the diabetes space and taking over Prothenas ATTR amyloidosis programme – including a Phase II-ready immunotherapy. more ➔
Sanofi invests heavily in multiple myeloma... Sanofi is shelling out US$1bn for a license granting the French pharma company access to a potential multiple myeloma treatment. more ➔
Bio-Me raises NOK10mOslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round. more ➔
NFL Biosciences goes public, raises €5mFrench biopharma company NFL Biosciences has raised €5m following its IPO at Euronext Growth Paris. more ➔
